GDF15 and ACE2 stratify COVID-19 patients according to severity while ACE2 mutations increase infection susceptibility
Coronavirus disease 19 (COVID-19) is a persistent global pandemic with a very heterogeneous disease presentation ranging from a mild disease to dismal prognosis. Early detection of sensitivity and severity of COVID-19 is essential for the development of new treatments. In the present study, we measu...
Saved in:
Published in | Frontiers in cellular and infection microbiology Vol. 12; p. 942951 |
---|---|
Main Authors | , , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Frontiers Media S.A
22.07.2022
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | Coronavirus disease 19 (COVID-19) is a persistent global pandemic with a very heterogeneous disease presentation ranging from a mild disease to dismal prognosis. Early detection of sensitivity and severity of COVID-19 is essential for the development of new treatments. In the present study, we measured the levels of circulating growth differentiation factor 15 (GDF15) and angiotensin-converting enzyme 2 (ACE2) in plasma of severity-stratified COVID-19 patients and uninfected control patients and characterized the
in vitro
effects and cohort frequency of ACE2 SNPs. Our results show that while circulating GDF15 and ACE2 stratify COVID-19 patients according to disease severity, ACE2 missense SNPs constitute a risk factor linked to infection susceptibility. |
---|---|
Bibliography: | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 Edited by: Vikas Sood, Jamia Hamdard University, India Reviewed by: Grégory Dubourg, IHU Mediterranee Infection, France; Devin Wahl, Colorado State University, United States These authors have contributed equally to this work and share first authorship This article was submitted to Virus and Host, a section of the journal Frontiers in Cellular and Infection Microbiology These authors have contributed equally to this work and share last authorship |
ISSN: | 2235-2988 2235-2988 |
DOI: | 10.3389/fcimb.2022.942951 |